| 000 | 00000nam 2200000zi 4500 |
| 001 | 9.955543 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20251031084827 |
|---|
| 006 | m o d f |
|---|
| 007 | cr cn |||||||| |
|---|
| 008 | 250919e202509 onc o f000 0 eng d |
|---|
| 020 | |a9780660790527 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-399/2025E-PDF |
|---|
| 245 | 00|aGuidance on expanded access clinical trials. |
|---|
| 264 | 1|aOttawa, ON : |bHealth Canada = Santé Canada, |cSeptember 2025. |
|---|
| 264 | 4|c©2025 |
|---|
| 300 | |a1 online resource (iii, 25 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Lignes directrices sur les essais cliniques à accès élargi. |
|---|
| 500 | |a"Date adopted 2025-09-29. Effective date 2025-09-29"--Cover. |
|---|
| 500 | |a"Pub.: 250230." |
|---|
| 650 | 0|aDrugs|xTesting|xGovernment policy|zCanada. |
|---|
| 650 | 0|aDrug accessibility|xGovernment policy|zCanada. |
|---|
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
|---|
| 775 | 08|tLignes directrices sur les essais cliniques à accès élargi.|w(CaOODSP)9.955544 |
|---|
| 856 | 40|qPDF|s807 KB|uhttps://publications.gc.ca/collections/collection_2025/sc-hc/H164-399-2025-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/clinical-trials/expanded-access.html |
|---|
| 986 | |a250230 |
|---|